Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 10/08/2009

    How do immune cells recognise infectious pathogens?

    Scientists of the University of Heidelberg and the German Cancer Research Centre have clarified the functional principles of an important receptor for bacterial infections: immune cells recognise bacterial and viral pathogens with a receptor known as toll-like receptor 9 (TLR9), which mediates biochemical reaction chains in order to fend off intruders. This discovery made by the Heidelberg researchers paves the way to develop new anti-infective…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-immune-cells-recognise-infectious-pathogens
  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Article - 28/02/2011 13779_de.jpg

    Development of food allergies

    Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
  • The Baden-Württemberg healthcare industry

    The pharmaceutical industry

    Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.

    https://www.gesundheitsindustrie-bw.de/en/location/pharma
  • Expert interview - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Press release - 24/09/2009

    Call for innovative technologies that address global health concerns

    The World Health Organization is seeking innovative technologies, in particular medical devices that offer solutions to global health concerns in low- and middle-income countries. The deadline for submission of proposals is January the 31st 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/call-for-innovative-technologies-that-address-global-health-concerns
  • Article - 21/11/2011 Schematic of a bacterial cell wall to which a layer of tale-shaped molecules is attached.

    Johannes Huebner's interest in intestinal bacteria and their sweet-sour capsule

    Some Enterococcus species are common commensal organisms in human intestines and other species are used in raw-milk cheese where they enhance flavour development. On the negative side enterococci are also a common cause of hospital-acquired infections. Prof. Dr. Johannes Huebner from the Freiburg University Medical Centre is hoping that the bacterias capsular polysaccharides might at some point in the future be used as a vaccine opening the door…

    https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-huebner-s-interest-in-intestinal-bacteria-and-their-sweet-sour-capsule
  • Article - 20/10/2014 22216_de.jpg

    Michael Schindler: HI virus and host interactions

    Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
  • Press release - 16/04/2008

    Effective Cancer Immune Therapy Through Order in the Blood Vessels

    Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
  • Press release - 30/07/2009

    Boehringer Ingelheim set to outpace the market again

    After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
  • Article - 27/01/2014 Discovery team members checking the settings of a mass spectrometer.

    immatics biotechnologies GmbH: active against cancer

    immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…

    https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
  • Press release - 28/05/2008

    Printed biochips

    In a collaborative project scientists in Stuttgart and Heidelberg succeeded in cutting the production costs for highly complex peptide arrays by a factor of 100 at the same time as being able to increase the number of functional peptides by a factor of 20.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/printed-biochips
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Press release - 30/10/2017 07777_de.jpg

    CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
  • Press release - 09/09/2010 China medical city logo

    China Medical City, Taizhou

    Taizhou is a commercial and industrial city of around 5 million inhabitants located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries on a total area of 25 square kilometers China Medical City CMC a national-level pharmaceutical high-tech park is currently under construction.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou
  • Funding

    EU4Health- Programme

    Funding programme, Funded by: European Union, Submission deadline: 31/12/2027
    https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
  • Article - 02/05/2016 hv_PhaZd1__C_WT.jpg

    Biopolymers – raw materials for innovative medical products

    Polyhydroxyalkanoates (PHA) are biodegradable biopolymers that are becoming increasingly important. Bioplastics are now used not only in everyday objects such as plastic bags and yogurt pots but also increasingly in the field of medicine, which is why intensive research into medical devices made from biodegradable polymers such as PHA has been going on for quite some time.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biopolymers-raw-materials-for-innovative-medical-products
  • Article - 12/09/2011 15319_de.jpg

    TransLimm brings new immunotherapies to patients more rapidly

    With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology.

    https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
  • Press release - 25/05/2021

    From harmless skin bacteria to dreaded pathogens

    The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/harmless-skin-bacteria-dreaded-pathogens
  • Press release - 04/02/2010 10640_de.jpg

    World Cancer Day: encouraging the prevention, detection and treatment of cancer

    World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
  • Dossier - 14/06/2010 11484_de.jpg

    Engineers of life

    Synthetic biology focuses on the development of biological systems with new defined characteristics assembled according to the principles of engineering. Synthetic biology has the potential to be used for a broad range of applications and has solutions in store for major problems of the future. It also fuels fears that human beings are playing the role of creators and going beyond natural boundaries.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/engineers-of-life
  • Article - 19/05/2008

    "Fast-track" route to a PhD degree

    The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fast-track-route-to-a-phd-degree
  • Article - 29/06/2015 Neher sitting in front of his computer, pointing at a drawing on the screen.

    How can influenza virus prediction be improved?

    Every February, the World Health Organisation (WHO) publishes recommendations on the composition of influenza virus vaccines for use in the upcoming influenza season. The WHO’s decision is based on observations and laboratory tests as well as experience and intuition. The particular type of influenza virus that is likely to be circulating in a given season has previously been mainly a matter of speculation. Richard Neher from the Max Planck…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-can-influenza-virus-prediction-be-improved
  • Press release - 12/10/2009

    Immatics appoints Carsten Reinhardt as Chief Medical Officer

    The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer

Page 7 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search